Reviewing Soligenix (SNGX) & Mateon Therapeutics (MATN)
Soligenix (NASDAQ: SNGX) and Mateon Therapeutics (NASDAQ:MATN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
This is a summary of current ratings and recommmendations for Soligenix and Mateon Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soligenix presently has a consensus target price of $7.33, suggesting a potential upside of 252.56%. Mateon Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 426.32%. Given Mateon Therapeutics’ higher probable upside, analysts plainly believe Mateon Therapeutics is more favorable than Soligenix.
This table compares Soligenix and Mateon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Soligenix has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
Institutional and Insider Ownership
8.8% of Soligenix shares are held by institutional investors. Comparatively, 8.6% of Mateon Therapeutics shares are held by institutional investors. 5.0% of Soligenix shares are held by insiders. Comparatively, 2.3% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Soligenix and Mateon Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Soligenix||$6.98 million||1.71||-$6.76 million||($1.36)||-1.53|
|Mateon Therapeutics||N/A||N/A||-$14.59 million||($0.54)||-0.70|
Soligenix has higher revenue and earnings than Mateon Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Soligenix beats Mateon Therapeutics on 8 of the 11 factors compared between the two stocks.
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.